Dec 21, 2025 04:00AM
Apr 10, 2025 05:32AM
Mar 21, 2025 07:44AM
Mar 21, 2025 06:47AM
Feb 26, 2025 09:35AM
Feb 26, 2025 08:10AM
Feb 25, 2025 07:00AM Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
Feb 25, 2025 06:45AM
Feb 13, 2025 08:00AM
Jan 14, 2025 06:44AM
Jan 13, 2025 12:21PM
Jan 13, 2025 11:20AM
Jan 12, 2025 04:00PM
Nov 25, 2024 08:23AM BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
Nov 25, 2024 07:01AM
Nov 25, 2024 07:00AM
Oct 10, 2024 08:21AM
Feb 16, 2024 07:46AM
Oct 6, 2023 07:00AM
Sep 13, 2023 04:57PM
Sep 13, 2023 04:57PM Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Sep 13, 2023 07:01AM
Sep 13, 2023 07:00AM
Aug 3, 2023 08:00AM
Jun 30, 2023 09:00AM
Jun 30, 2023 09:00AM
May 22, 2023 05:46AM
May 20, 2023 10:50AM Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
May 4, 2023 08:00AM
Feb 23, 2023 08:00AM
Feb 21, 2023 08:01AM
Feb 21, 2023 08:00AM
Jun 15, 2022 09:09AM
May 23, 2022 07:01AM
May 23, 2022 07:00AM Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Apr 28, 2022 08:00AM
Apr 4, 2022 04:17PM
Apr 4, 2022 11:46AM
Apr 4, 2022 08:15AM
Apr 4, 2022 07:34AM
Apr 4, 2022 07:30AM
Mar 1, 2022 07:01AM Alnylam Pharma (ALNY) Announces FDA Acceptance of sNDA for OXLUMO for Treatment of Advanced Primary Hyperoxaluria Type 1
Mar 1, 2022 07:00AM
Feb 17, 2022 09:18AM
Feb 11, 2022 07:21AM
Feb 11, 2022 05:13AM
Jan 21, 2022 07:30AM
Jan 21, 2022 07:30AM
Jan 14, 2022 07:03AM Alnylam Pharma (ALNY) Will Report Full 18-Month HELIOS-A Phase 3 Study of Vutrisiran Results SFNP Meeting
Jan 14, 2022 07:00AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All